154 related articles for article (PubMed ID: 16850492)
1. The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant.
Aerts JG; Delahaye M; van der Kwast TH; Davidson B; Hoogsteden HC; van Meerbeeck JP
Diagn Cytopathol; 2006 Aug; 34(8):523-7. PubMed ID: 16850492
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
[TBL] [Abstract][Full Text] [Related]
3. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
4. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
5. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study.
Saad RS; Cho P; Liu YL; Silverman JF
Diagn Cytopathol; 2005 Mar; 32(3):156-9. PubMed ID: 15690334
[TBL] [Abstract][Full Text] [Related]
6. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
7. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and prognosis in malignant pleural mesothelioma: a prospective study.
Mårtensson G; Hagmar B; Zettergren L
Eur J Respir Dis; 1984 Apr; 65(3):169-78. PubMed ID: 6723826
[TBL] [Abstract][Full Text] [Related]
9. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.
Bueno R; Reblando J; Glickman J; Jaklitsch MT; Lukanich JM; Sugarbaker DJ
Ann Thorac Surg; 2004 Nov; 78(5):1774-6. PubMed ID: 15511473
[TBL] [Abstract][Full Text] [Related]
10. The role of cytological evaluation of pleural fluid in diagnosing malignant mesothelioma.
Lovrenski A; Panjković M; Tegeltija D; Latinović LT; Krcedinac J
Med Pregl; 2012; 65(1-2):5-8. PubMed ID: 22452231
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma.
Greillier L; Cavailles A; Fraticelli A; Scherpereel A; Barlesi F; Tassi G; Thomas P; Astoul P
Cancer; 2007 Nov; 110(10):2248-52. PubMed ID: 17886249
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic efficacy of electron microscopy and pleural effusion cytology for the distinction of pleural mesothelioma and lung adenocarcinoma.
Domínguez-Malagón H; Cano-Valdez AM; González-Carrillo C; Campos-Salgado YE; Lara-Garcia A; Lopez-Mejia M; Corona-Cruz JF; Arrieta O
Ultrastruct Pathol; 2016; 40(5):254-60. PubMed ID: 27405014
[TBL] [Abstract][Full Text] [Related]
13. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.
Kobzik L; Antman KH; Warhol MJ
Acta Cytol; 1985; 29(3):219-25. PubMed ID: 3859121
[TBL] [Abstract][Full Text] [Related]
14. [Tissue polypeptide antigen as a biological marker of malignant pleural mesothelioma].
Tokuyama T; Okamoto Y; Hamada K; Yoneda T; Narita N; Tamura M; Kitamura K; Maruyama H; Takezawa Y; Yamada Y
Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Jun; 35(6):609-15. PubMed ID: 9294293
[TBL] [Abstract][Full Text] [Related]
15. [Diagnosis of malignant pleural mesothelioma--thoracoscopic biopsy and tumor marker].
Suzuki K
Nihon Geka Gakkai Zasshi; 2009 Nov; 110(6):333-7. PubMed ID: 19999567
[TBL] [Abstract][Full Text] [Related]
16. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
17. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit.
Segal A; Sterrett GF; Frost FA; Shilkin KB; Olsen NJ; Musk AW; Nowak AK; Robinson BW; Creaney J
Pathology; 2013 Jan; 45(1):44-8. PubMed ID: 23222247
[TBL] [Abstract][Full Text] [Related]
18. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
Matsumoto S; Nabeshima K; Kamei T; Hiroshima K; Kawahara K; Hata S; Marukawa K; Matsuno Y; Taguchi K; Tsujimura T
Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of pleural malignant mesothelioma in life--a practical approach.
Whitaker D; Shilkin KB
J Pathol; 1984 Jul; 143(3):147-75. PubMed ID: 6379132
[TBL] [Abstract][Full Text] [Related]
20. Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma.
Shin HJ; Shin DM; Tarco E; Sneige N
Cancer; 2003 Aug; 99(4):233-9. PubMed ID: 12925985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
